INSYS Therapeutics
NASDAQ:INSYInsys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
Kazia Therapeutics
NASDAQ:KZIAKazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
OHR Pharmaceutical
NASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Pharmaxis
OTCMKTS:PXSLYPharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Teligent
NASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.